Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial.
Firooz
Alireza
A
Solhpour
Amirreza
A
Gorouhi
Farzam
F
Daneshpazhooh
Maryam
M
Balighi
Kamran
K
Farsinejad
Khalil
K
Rashighi-Firoozabadi
Mehdi
M
Dowlati
Yahya
Y
D000279:Administration, Cutaneous; D000328:Adult; D065095:Calcineurin Inhibitors; D012628:Dermatitis, Seborrheic / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D019696:Peptidylprolyl Isomerase / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; C021650:hydrocortisone acetate; C117268:pimecrolimus; D019696:Peptidylprolyl Isomerase; D006854:Hydrocortisone; D016559:Tacrolimus